NCT07421414

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions

A Randomized, Open-label, Fed, Oral Administration, Single Dose, 2-sequence, 4-period, Crossover Study to Evaluate the Pharmacokinetics and Safety After Administration of "BR1015-A" and Co-administration of "BR1015-3" and "BR1015-2" in Healthy Adult Volunteers

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	BR1015-A	Fimasartan 30 mg/Indapamide 1.5 mg
DRUG	BR1015-3	Fimasartan 30 mg
DRUG	BR1015-2	Indapamide 1.5 mg

Timeline

• Start date: 2026-04-19
• Primary completion: 2026-06-17
• Completion: 2026-06-17
• First posted: 2026-02-19
• Last updated: 2026-02-19